Evidence map›Paper›PMID 39630008›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Interfacial cfDNA Enrichment and Amplification with On-Chip Thermoplasmonics for Highly Sensitive Cancerous Liquid Biopsy.

Danhua Wang, Linlin Liu, Wenjing Chi, Zhenping Liu, Jiayun Wu, Yirou Liang, Fei He, Ruixiang Zhang, Pengxin Huang, Yunbo Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Danhua WangInstitute of Medical Robotics, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
Linlin LiuInstitute of Medical Robotics, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
Wenjing ChiDepartment of Laboratory Medicine, Huadong Hospital Affiliated to Fudan University, Shanghai, 200031, China.
Zhenping LiuThe First People's Hospital of Linping District, Hangzhou, Zhejiang Province, 311100, China.
Jiayun WuInstitute of Medical Robotics, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
Yirou LiangInstitute of Medical Robotics, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
Fei HeInstitute of Medical Robotics, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
Ruixiang ZhangInstitute of Medical Robotics, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
Pengxin HuangInstitute of Medical Robotics, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
Yunbo LiInstitute of Medical Robotics, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
Guangyu QiuInstitute of Medical Robotics, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.ORCID https://orcid.org/0000-0001-7873-1485

Funding

Fundamental Research Funds for the Central Universities YG2023QNA41Fundamental Research Funds for the Central Universities YG2024QNB28National Key Research and Development Program of China 2023YFD2402600National Natural Science Foundation of China 22404110Shanghai Municipal Science and Technology Major Project 2021SHZDZX
6 · The paper itself

Abstract

Tumor-derived cell-free DNA (cfDNA) has been exploited as an effective liquid biopsy biomarker for early cancer diagnosis. However, the fragmented and low-abundance nature in circulating blood pose challenges for highly sensitive cfDNA quantification. Herein, a multifunctional plasmonic biosensor termed Interfacial cfDNA Enrichment, Amplification and Sensing with on-chip Thermoplasmonics (INEAST) is developed for cfDNA-based liquid biopsy and lung cancer diagnosis. The INEAST biosensor achieved in situ thermoregulation and label-free cfDNA biosensing by simultaneously harnessing interfacial thermoplasmonics and localized surface plasmon resonance. Typical cfDNA biomarkers, including epidermal growth factor receptor (EGFR), tumor protein 53 (TP53), phosphatase and tensin homologue deleted on chromosome 10 (PTEN), and cyclin-dependent kinase inhibitor (CDKN2A), are quantified with detection limits down to femtomolar-level. Through further validation using blood samples from lung cancer patients, the proposed INEAST bioassays demonstrated superior reliability for lung cancer screening, particularly when combined with clinically available tumor-protein metrics. This study demonstrated that the INEAST biosensor enables rapid and sensitive cfDNA quantification, yielding a promising and compatible liquid biopsy for early-stage lung cancer diagnosis.

Indexed as

Biomarkers, TumorBiosensing TechniquesCell-Free Nucleic AcidsCirculating Tumor DNALung NeoplasmsHumansLab-On-A-Chip DevicesLiquid BiopsySurface Plasmon ResonanceBiomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNAbiosensorscell‐free DNAliquid biopsylung cancernucleic acid amplificationthermoplasmonics

Identifiers

PMID39630008
PMCPMC11789577

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.